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Are Expired Drugs Dangerous? 
A recent drug information question we received was: “Are expired drugs dangerous?” The short answer is that 
not all expired drugs are dangerous. Some drugs that degrade easily (e.g. sublingual nitroglycerin, insulin, liq-
uid antibiotics) would be dangerous if expired because of loss of potency and subsequent loss of therapeutic 
benefit. Others that decompose into a different chemical compound (e.g. aspirin degrades to salicylic acid) 
could be dangerous. To understand the issue more closely, there are 2 questions to consider:  
 
(1) Who sets the expiration dates for prescription drugs in their original packaging?  
Expiration dates are set by the manufacturer of a prescription drug and not by the healthcare authorities. The 
company may choose time period that is determined based on the results of "in-house" testing. Some people, 
however, feel that the time period chosen by the company is done in an effort to facilitate product sales. Most 
pharmaceutical manufacturers choose two to three years after the date of manufacture as the expiration date. 
The expiration date assigned to a medication by the manufacturer is not the date after which it has "gone bad." 
It is the date after which the manufacturer cannot guarantee that the product meets standards for stability 
(maintaining identity, strength, quality, purity). Usually, all products should maintain at least 90% potency till 
the shelf life mentioned on them. 
 
(2) Who sets the expiration dates for prescription drugs that are transferred from original packaging 
into a prescription container?  
In 1985, the United States Pharmacopoeia (USP) began recommending that pharmacists set expiration dates at 
no more than one year if they are dispensing drugs in a container other than the original one. In 1997, it be-
came a USP requirement that, unless otherwise specified in compendium standards, the expiration date on a 
dispensed medication should be no later than the expiration date on the manufacturer’s container or one year 
from the dispensing date, whichever is earlier. How a medication is stored affects its long-term stability.      
Exposure to light, air, humidity, and temperature extremes can affect the degradation rate of a drug. The expi-
ration date assigned by the manufacturer or dispensing pharmacist assumes that the medication will be stored 
properly, with in the closed container it was actually dispensed in and stored at the appropriate temperature. In 
reality, many patients store medications in less than ideal environments: warm, humid areas (bathroom cabi-
net), window sills (lighted areas), various locations in the interior of automobiles (hot) etc. 
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These storage conditions lend credence to pharmaceutical manufacturers’ insistence that "conservative" 
expiration dating is warranted. 
 
Therefore the main idea is that not to take risk in using expired medications unless confirmed by healthcare     
authorities and manufacturer about the extension of shelf life beyond expiration date only under special circum-
stances like  shortage of drugs  or anticipation of large inventory losses as a result of expiry. 
 
Syed Shamim Raza (Senior  Pharmacist II)  
 
Why Report Adverse Drug Reactions? 
 
• Because the data about Asians is very limited as compared to Caucasians 
• Many ADRs are preventable  
• It helps in restricting use of unsafe drugs 
• It helps Pharmacy & Therapeutic Committee to make and implement protocols for safe use of medicines 
 
Report ADRs, “Patient’s Safety” should be our first priority!   
 
 
ADR Reportage—Year wise Presentation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Compiled by: Drug & Poison Information Centre, Department of Pharmacy Services—AKUH 
Year  2000 2001 2002 2003 2004 
# of ADRs 43 87 55 40 78 
Specialty of person reporting   
Pharmacist  17 09 38 27 49 
Physician  24 78 11 08 29 
Nurses  02 - 06 05 - 
Age of  the patients distributed in each year 
Max. age 72 years 83 years 80 years 73 years  84 years 
Min. age  11 months 2 years 1 year  1 year  8 months 
Sex of the patient 
Males # 23 50 26 29 31 
Females # 20 37 29 11 47 
Recovered  100 98 100 97 96 
Fatal  - 2 - 3 4 
Severity (outcome) of ADRS (%)  
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NEWS ALERT!  Use of Promethazine (Phenargan) in Children 
 
Dear Health Care Professional: 
Based on a review of adverse events for Phenergan in pediatric patients, the Food and Drug Administration has 
requested that the following changes, be made to the product prescribing information effective from 31st    
January 2005. 
 
CONTRAINDICATIONS : 
Phenergan Tablets, injections and syrup are contraindicated for use in pediatric patients less than two years of  
age. 
 
WARNINGS 
Phenergan should not be used in pediatric patients less than 2 years of age because of the potential for fatal 
respiratory depression. Postmarketing cases of respiratory depression, including fatalities have been reported 
with its use in children < 2 years old. A wide range of weight-based doses of Phenergan have resulted in respi-
ratory depression in these patients. Caution should be exercised when administering Phenergan to the pediatric 
patients < 2 years old and older. It is recommended that the lowest effective dose of Phenergan be used and 
concomitant administration of other drugs with respiratory depressant effects be avoided. 
Categories of ADRs reported Trough Year 2000-2004
GI Drugs 7%
Analgesics 4%
CNS drugs 10%
Cardiovascular Drugs 
10%
Hematological Agents 
10%
Chemotherapeutic 
Agents 11%
Antibiotics 48%
Antibiotics
Chemotherapeutic Agents
Hematological Agents
Cardiovascular Drugs
CNS drugs
GI Drugs
Analgesics
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Important Drug Warning - Herceptin (Trastuzumab) 
Caution for Oncologists and Cardiologists 
This is  updated cardiotoxicity information related to the use of HERCEPTIN® (trastuzumab), 
obtained from the National Surgical Adjuvant Breast and Bowel Project (NSABP) study (B-31), a randomized, 
Phase III trial that was conducted in 2043 women with operable, HER2 over expressing breast cancer (IHC 3+ 
or FISH+). This study demonstrated a significant increase in cardiotoxicity in patients who were randomized 
to the HERCEPTIN-containing arm as compared to patients who received chemotherapy alone. 
A preliminary analysis of the safety data from Study NSABP B-31 was presented at the annual meeting of the 
American Society of Clinical Oncology (ASCO) in May 2005, during the presentation of a joint analysis of 
Study NSABP B-31 and the North Central Cancer Treatment Group (NCCTG) study (N9831). Study NSABP 
B-31 was intended, in part, to characterize cardiotoxicity associated with HERCEPTIN use and to assess the 
value of serial cardiac monitoring during HERCEPTIN therapy as a predictor of cardiotoxicity and as an aid to 
early identification of cardiac toxicity. 
Based on preliminary data and analyses through April 2005, 6.8% of patients were unable to initiate         
HERCEPTlN per the protocol because of decreased LVEF or symptoms of cardiac toxicity experienced during 
the AC portion of therapy. Among the evaluable patients who had adequate cardiac function and initiated 
HERCEPTIN, 30.5% required at least one dose delay because of asymptomatic decrease in LVEF or cardiac 
symptoms. In 18.6% of patients, HERCEPTIN was discontinued prior to the completion of 1 year of therapy 
because of asymptomatic decrease in LVEF (14.3%) and symptomatic cardiac dysfunction/other cardiac toxic-
ity (4.3%). In addition, a statistically significant increase in the 3-year cumulative incidence of New York 
Heart Association Class III and IV congestive heart failure and cardiac death was observed in patients who    
received the HERCEPTIN-containing regimen (4.1%) compared with control (0.8%). There were no cardiac 
deaths observed in patients who received the HERCEPTIN-containing regimen and 1 cardiac death was       
observed in the control arm. Final analysis of the cardiac safety data collected in Studies NSABP B-31 and 
NCCTG N9831 is ongoing. 
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